Summary
Guinea pigs, having developed cutaneous tuberculin hypersensitivity after immunization with BCG were treated for 10 days by intraperitoneal injections of moderately toxic doses of cyclophosphamide, triethylene melamine, ibenzmethyzin, 6-MP, amethopterin (6 injections in 13 days), actinomycin C, vinblastine, podophyllin derivative, prednisolone and phenylbutazone. After 5 days of treatment tuberculin reaction was suppressed in most animals by 6-MP, whereas the other substances had only moderate or no effect. After 10 days of treatment, however, tuberculin reactions were markedly diminished by nearly all applied substances with exception of vinblastine, TEM and amethopterin, which caused only weak effects. Inspite of nearly complete inhibition of the tuberculin reaction at the end of treatment with 6-MP and ibenzmethyzin a state of tolerance never developed. There was a correlation between the intensity of tuberculin reaction and the number of small lymphocytes with a pale cytoplasm in the blood. An unspecific inflammation, Rebuck's skin window (like the tuberculin reaction characterized by an intensive mononuclear cell infiltration), caused simultaneously with the tuberculin reaction immediately after the period of treatment was more or less markedly diminished by 6-MP, TEM, cyclophosphamide, ibenzmethyzin, podophyllin derivative and actinomycin. The notably good inhibition of an immunological reaction of the delayed type by a large scale of different substances in our experiments is explained by an immunosuppressive effect of all and an anti-inflammatory effect of some substances and by some kind of immunoparalysis caused by frequent injections of antigen.
Similar content being viewed by others
Literatur
Aisenberg, A. C.: Nature (Lond.)200, 484 (1963).
Arnason, B. G., andB. H. Waksman: Fortschr. Tuberk.-Forsch.13, 1–97 (1964).
Baker, R., R. Gordon, J. Huffer, andG. H. Miller, Jr.: Arch. Surg.65, 702–705 (1952).
Begemann, H.: Ärztl. Fortbild.17 (1968) (im Druck).
Berenbaum, M. C.: Nature (Lond.)196, 384–385 (1962).
—: Nature (Lond.)198, 606–607 (1963).
—, andJ. N. Brown: Nature (Lond.)200, 84 (1963).
Billingham, R. E., P. L. Krohn, andP. B. Medawar: Brit. med. J.1951 I, 1157–1163.
Bohrod, M. G.: Progr. Allergy4, 31–78 (1954).
Bollag, W.: Experientia (Basel)19, 304–307 (1963).
Borel, Y., andR. Schwartz: J. Immunol.92, 754–761 (1964).
Brodehl, J.: Z. Immun.-Forsch.113, 343 (1956).
Condie, R. M., W. J. Mennis, andC. Miller: Fed. Proc.20, 26 (Abstr.) (1961).
Cline, M. J.: Blood30, 176–188 (1967).
Dammin, G. J., andS. C. Bukantz: J. Amer. med. Ass.139, 358–362 (1949).
Domenjoz, R.: Pharmakologie der nichthormonellen Antiphlogistika. InR. Heister u.H. F. Hofmann (Herausgeb.): Die Entzündung, S. 244–252. München-Berlin-Wien: Urban & Schwarzenberg 1966.
Dougherty, T. F.: Progr. Allergy4, 319–360 (1954).
Etteldorf, J. N., S. Roy, R. L. Summitt, M. J. Sweeney, H. P. Wall, andW. M. Berton: J. Pediat.70, 758–766 (1967).
Favez, G.: The influence of oxyphenbutazone on specific circulating antibodies during active tuberculosis in man. InJ. Lindner u.E. Wilhelmi (Herausgeb.): Die infektiöse Entzündung, S. 383–385. Bern-Stuttgart: Huber 1968.
Floersheim, G. L.: Experientia (Basel)19, 546–547 (1963).
—: Helv. physiol. pharmacol. Acta22, C 121-C 123 (1964).
- In S.Garattini and M. N. G.Dukes (Ed.): Non-steroidal anti-inflammatory drugs, pp. 232–235. Amsterdam-New York-London-Milan-Tokyo-Buenos Aires 1965.
Follis, R. H., Jr.: Bull. Johns Hopk. Hosp.63, 283–299 (1938).
Fukase, M.: Tohoku J. exp. Med.89, 349–362 (1966).
Gell, P. G. H., andB. Benacerrat: Advanc. Immunol.1, 319–343 (1961).
—, andI. T. Hinde: Bull. schweiz. Äkad. med. Wiss.8, 200–202 (1952).
Genghof, D. S., andJ. R. Battisto: Proc. Soc. exp. Biol. (N.Y.)107, 933–936 (1961).
Gillissen, G.: Klin. Wschr.43, 590–597 (1965).
Gowans, J. L., andD. D. McGregor: Progr. Allergy9, 1–78 (1965).
Gubner, R., S. August, andV. Ginsberg: Amer. J. med. Sci.221, 176–182 (1951).
Hektoen, L., andH. J. Corper: J. infect. Dis.28, 279–285 (1921).
Hersh, E. M., V. G. Wong, andE. J. Ferireich: Blood27, 38–48 (1966).
Hitchings, G. H., andG. B. Elion: Pharmacol. Rev.15, 365–405 (1963).
Hoffmann, E.: Tuberk.-Arzt9, 464–472 (1955).
Hoyer, J., andR. M. Condie: Fed. Proc.21, 277 (Abstr.) (1962).
Hoyer, L. W., R. A. Good, andR. M. Condie: J. exp. Med.116, 311–327 (1962).
Hoyer, J. R., L. W. Hoyer, R. A. Good, andR. M. Condie: J. exp. Med.116, 679–685 (1962).
Humphreys, S. R., M. A. Chirigos, K. L. Milstead, N. Mantel, andA. Goldin: J. nat. Cancer Inst.27, 259–276 (1961).
Hunstein, W., u.M. Strey: Klin. Wschr.43, 52–53 (1965).
Jones, J. W., R. Oneal, R. Haines, andG. Rosin: Fed. Proc.21, 40 (1962).
Kaboth, W., F. Trepel, P. Schick, G. Wernekke u.H. Begemann: Z. ges. exp. Med.148, 306–336 (1968).
Kistler, H.: Int. Arch. Allergy10, 361–375 (1957).
Kosunen, T. U., W. S. Tihen, andB. H. Waksman: Fed. Proc.21, 274 (1962).
Kuwert, E.: Der Einfluß von Oxyphenylbutazon und Phenylbutazon auf den Ablauf der experimentellen Immunencephalitis. InJ. Lindner u.E. Wilhelmi: Die infektiöse Entzündung, S. 117–126. Bern-Stuttgart: Huber 1968.
Lagrue, G., B. N. Halpern, J. Bariéty, P. Samarcg, A. Fray etP. Milliez: C.R. Soc. Biol. (Paris)159, 322 (1965).
Lange, A.: Z. Rheumaforsch.20, 203–208 (1961).
LaPlante, E. S., R. M. Condie, andR. A. Good: J. Lab. clin. Med.59, 542–549 (1962).
Leder, L.-D., u.R. Nicolas: Frankfurt. Z. Path.72, 632 (1963).
Long, D. A., andP. C. Spensley: Lancet1954 I, 645–647.
Lorenzen, I., andA. Videbaek: Lancet1965 II, 558–561.
Maguire, H. C., Jr., andH. J. Maibach: J. Invest. Derm.37, 427–431 (1961).
Maguire, H., andE. Steers: Experientia (Basel)19, 591–592 (1963).
McCluskey, R. T., B. Benacerraf, andJ. W. McCluskey: J. Immunol.90, 466–477 (1963).
McQuarrie, D. G., R. M. Condie, W. R. Meeker, F. Roller, andR. L. Varco: Proc. Soc. exp. Biol. (N.Y.)103, 278–282 (1960).
Medawar, P. B., andE. M. Sparrow: J. Endocr.14, 240–256 (1956).
Meier, R., u.F. Gross: Dtsch. med. Wschr.76, 1179–1181 u. 1241–1243 (1951).
Moeschlin, S., R. Báguena, andJ. Báguena: Int. Arch. Allergy4, 83–100 (1953).
Najarian, J. S., andJ. D. Feldman: J. exp. Med.114, 779–789 (1961).
Page, A. R., R. M. Condie, andR. A. Good: Amer. J. Path.40, 519–530 (1962).
— — —: Blood20, 118–119 (1962).
Potel, J.: Arzneimittel-Forsch.15, 527–532 (1965).
—, u.N. Brock: Arzneimittel-Forsch.15, 659–666 (1965).
Prendergast, R. A.: J. exp. Med.119, 377–387 (1964).
Rebuck, J. W., andJ. H. Crowley: Ann. N.Y. Acad. Sci.59, 757–805 (1955).
Rothschild, H., J. S. Friedenwald, andC. Bernstein: Bull. Johns Hopk. Hosp.54, 232 (1934); zit. n. R. H.Follis, Jr.: Bull. Johns Hopk. Hosp.63, 283 (1938).
Schick, P., F. Trepel u.H. Begemann: Z. ges. exp. Med.148, 275–305 (1968).
Schwartz, R. S.: Progr. Allergy9, 246–303 (1965).
—, andL. Beldotti: Science149, 1511–1514 (1965).
Scothorne, R. J.: J. Anat. (Lond.)90, 417–427 (1956).
Steffen, C.: Allgemeine und experimentelle Immunologie und Immunpathologie. Stuttgart: Thieme 1968.
Stender, H. S., D. Strauch, H. Winter u.W. Textor: Arzneimittel-Forsch.13, 1031–1034 (1963).
Studer, A.: Bull. schweiz. Akad. med. Wiss.8, 60–66 (1952).
Tolderlund, K., K. Bunch-Christensen, andH. Waaler: Bull. Wld Hlth Org.22, 177–184 (1960).
Trepel, F., u.H. Begemann: Acta haemat. (Basel)36, 386–398 (1966).
—,G. Gerstmair, R. Waubke, H. Pichlmaier u.H. Begemann: Haematologia1, 119–129 (1967).
—, u.J. Rastetter: Blut15, 76–82 (1967).
-, P.Schick u. H.Begemann: Wirkung verschiedener Zytostatika und Antiphlogistika auf die zelluläre Entzündungsreaktion. Folia haemat. (im Druck).
Turk, J. L.: Int. Arch. Allergy24, 191–200 (1964).
—,C. J. Heather, andJ. V. Diengdoh: Int. Arch. Allergy29, 278–289 (1966).
Uehlinger, E., u.R. Siebenmann: Bull. schweiz. Akad. med. Wiss.8, 203–212 (1952).
Vollmer, H.: J. Pediat.39, 22–32 (1951).
Vorlaender, K. O.: Z. ärztl. Fortbild.16, 4–10 (1967).
Waksman, B. H.: Tissue damage in the “delayed” (cellular) type of hypersensitivity. In: Mechanism of Cell and Tissue Damage Produced by Immune Reactions. II. Internat. Symposium on Immunopathology 1961, Basel-Stuttgart: Schwabe 1962, p. 146–159.
Waubke, R., G. Gerstmair, F. Trepel, H. Pichlmaier u.H. Begemann: Haematologia (Budapest)1, 45–60 (1967).
Weiler, E.: Science144, 846–849 (1964).
Wiener, J., D. Spiro, andH. O. Zunker: Amer. J. Path.47, 723–763 (1965).
Wirostko, E., andS. P. Halbert: J. exp. Med.116, 653–663 (1962).
Wust, C. J., C. L. Gall, andG. D. Novelli: Science143, 1041–1043 (1964).
Zollinger, H. U., M. Enderlin u.O. Spühler: Bull. schweiz. Akad. med. Wiss.8, 162–168 (1952).
Author information
Authors and Affiliations
Additional information
Diese Untersuchungen wurden durch die Deutsche Forschungsgemeinschaft ermöglicht.
Wir danken den Firmen Asta-Werke, Brackwede, Farbwerke Hoechst, Frankfurt, Hoffmann-La Roche, Basel, Burroughs and Wellcome, London, Lederle, München, Farbenfabriken Bayer, Leverkusen, E. Lilly, Gießen, Sandoz, Nürnberg, und E. Merck, Darmstadt, für die Bereitstellung der Substanzen.
Rights and permissions
About this article
Cite this article
Trepel, F., Schick, P. & Begemann, H. Morphologische und funktionelle Veränderungen im Blutzellsystem des Meerschweinchens nach Behandlung mit cytostatischen Substanzen, Prednisolon und Phenylbutazon. Z. Gesamte Exp. Med. 149, 25–43 (1969). https://doi.org/10.1007/BF02203434
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02203434